Tenderwize
Retour à la recherche

Pharmaceutical discount agreements with joining option

BARMER Beschaffung und Vergabe·Wuppertal, Germany·Deadline May 01, 2027 · 245 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarder
Titre original de l'avis

Germany – Pharmaceutical products – Arzneimittelrabattverträge mit Beitrittsoption

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

Critical information such as estimated value, award criteria, and eligibility requirements are not provided in the noti...

The notice disclaims applicability of EU procurement directives, which may reduce legal recourse in case of disputes.

No procurement documents available

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2027
  • Supply of pharmaceutical products containing the active ingredient Lercanidipin.
  • Framework agreement with a joining option (Beitrittsoption), allowing other entities to join.
Afficher le résumé complet

This is a voluntary transparency notice for a framework agreement with a joining option for pharmaceutical products, specifically the active ingredient Lercanidipin, issued by BARMER. The framework runs from 1 May 2025 to 30 September 2027, with a possible extension of 3 months. The notice explicitly states it is not a public procurement under EU Directive 2014/24/EU. Submission deadline is 1 May 2027 at 10:35 CEST. No estimated value or award criteria are provided.

Risques

Critical information such as estimated value, award criteria, and eligibility requirements are not provided in the noti...

The notice disclaims applicability of EU procurement directives, which may reduce legal recourse in case of disputes.

No procurement documents available

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The notice is not a public procurement under EU Directive 2014/24/EU; it is a voluntary transparency notice.
  • Multiple tenders are allowed (up to 999).
  • Variants are not allowed.

Acheteur

Localisation

Wuppertal, DEU

Identifiant

992-80322-57

Activité

Health

Lots (1)

LOT-0000

Pharmaceutical discount agreements with joining option

Framework agreement for the supply of pharmaceutical products containing the active ingredient Lercanidipin. The framework includes a one-time extension option of 3 months until 30 September 2027. Details are available in the procurement documents.

SuppliesFrameworkEU fundedElectronic submission

Durée

Apr 2025 - Sep 2027

Catégorie

Pharmaceutical products

Date limite

Deadline May 01, 2027

Détails de la procédure

Date de publication
26 Mar 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
197516-2025

Documents (1)

Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30